How to buy Acer Therapeutics stock (ACER)

Acer Therapeutics is a biotechnology business based in the US. Acer Therapeutics shares (ACER) are listed on the NASDAQ and all prices are listed in US Dollars. Acer Therapeutics employs 30 staff and has a trailing 12-month revenue of around $360,000.

Our top picks for where to buy Acer Therapeutics stock

Buy Acer Therapeutics stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Acer Therapeutics stock price (NASDAQ: ACER)

Use our graph to track the performance of ACER stocks over time.

Acer Therapeutics shares at a glance

• Key figures

Information last updated 2024-10-13.

52-week range	$0.90 - $0.90
50-day moving average more info button	$0.81
200-day moving average more info button	$0.97
Wall St. target price	$1.50
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-1.93

Is it a good time to buy Acer Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Acer Therapeutics financials

Revenue TTM	$360,000
Gross profit TTM	$1.3 million
Return on assets TTM	-65.27%
Return on equity TTM	-472.99%
Profit margin	0%
Book value	$-1.36
Market Capitalization more info button	$16.1 million

TTM: trailing 12 months

Acer Therapeutics share dividends

We're not expecting Acer Therapeutics to pay a dividend over the next 12 months.

Have Acer Therapeutics's shares ever split?

Acer Therapeutics's shares were split on a 751:7777 basis on 20 September 2017 . So if you had owned 7777 shares the day before before the split, the next day you'd have owned 751 shares. This wouldn't directly have changed the overall worth of your Acer Therapeutics shares – just the quantity. However, indirectly, the new 935.6% higher share price could have impacted the market appetite for Acer Therapeutics shares which in turn could have impacted Acer Therapeutics's share price.

Acer Therapeutics share price volatility

Over the last 12 months, Acer Therapeutics's shares have ranged in value from as little as $0.9 up to $0.9. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Acer Therapeutics's is 0.441. This would suggest that Acer Therapeutics's shares are less volatile than average (for this exchange).

Acer Therapeutics overview

Acer Therapeutics Inc. , a pharmaceutical company, focuses on the acquisition, development, and commercialization of therapies for serious rare and life-threatening diseases. The company's pipeline includes four clinical-stage candidates comprising EDSIVO for the treatment of vascular Ehlers-Danlos Syndrome in patients with a confirmed type III collagen mutation; ACER-801 for the treatment of induced Vasomotor Symptoms, post-traumatic stress disorder, and prostate cancer; and OLPRUVA, a formulation of sodium phenylbutyrate for the treatment of various inborn errors of metabolism, including urea cycle disorders and maple syrup urine disease. It has a license agreement with Sanofi to acquire worldwide rights to Osanetant, a clinical-stage, selective, and non-peptide tachykinin NK3 receptor antagonist; an option agreement with Relief for the development, regulatory approval, and commercialization of OLPRUVA; and an agreement with Emory University to acquire the worldwide intellectual property rights to a family of patents and patent applications related to the use of neurokinin receptor antagonists in managing conditioned fear and treating anxiety disorders, including post-traumatic stress disorder. The company was incorporated in 1991 and is headquartered in Newton, Massachusetts. As of November 17, 2023, Acer Therapeutics Inc. operates as a subsidiary of Zevra Therapeutics, Inc.

Frequently asked questions

null
What percentage of Acer Therapeutics is owned by insiders or institutions?
Currently 13.78% of Acer Therapeutics shares are held by insiders and 29.911% by institutions. How many people work for Acer Therapeutics?
Latest data suggests 30 work at Acer Therapeutics. When does the fiscal year end for Acer Therapeutics?
Acer Therapeutics's fiscal year ends in December. Where is Acer Therapeutics based?
Acer Therapeutics's address is: One Gateway Center, Newton, MA, United States, 02458 What is Acer Therapeutics's ISIN number?
Acer Therapeutics's international securities identification number is: US00444P1084 What is Acer Therapeutics's CUSIP number?
Acer Therapeutics's Committee on Uniform Securities Identification Procedures number is: 7171EN106